R R

What Is Rebif?

Rebif is a prescription medication containing interferon beta-1a, a laboratory-produced form of a naturally occurring immune signaling protein. It is a disease-modifying therapy used to treat relapsing forms of multiple sclerosis (MS) in adults. These include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Rebif is administered by subcutaneous injection three times weekly and is available in prefilled syringes and autoinjector presentations. It can reduce disease activity but does not cure MS or reverse existing neurological damage. Patients require monitoring for liver problems, blood cell changes, and other adverse reactions.

Link to This Resource Page

Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.

To display this...

What Is Rebif?

Rebif is a prescription medication containing interferon beta-1a, a laboratory-produced form of a naturally occurring immune signaling protein. It is a disease-modifying therapy used to treat relapsing forms of multiple sclerosis (MS) in adults. These include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS. Rebif is administered by subcutaneous injection three times weekly and is available in prefilled syringes and autoinjector presentations. It can reduce disease activity but does not cure MS or reverse existing neurological damage. Patients require monitoring for liver problems, blood cell changes, and other adverse reactions.

read more about rebif ...

Copy this HTML:

Copy HTML Copied!

How Does Rebif Work?

Rebif contains interferon beta-1a, which binds to interferon receptors on human cells and activates signaling pathways involved in immune regulation. These effects influence the activity of immune cells and the production of proteins involved in inflammatory responses. In multiple sclerosis, abnormal immune activity damages myelin, the protective covering around nerve fibers in the central nervous system. Interferon beta-1a can reduce the frequency of relapses and influence disease activity, although its precise therapeutic mechanism in MS is not fully established. Rebif modifies aspects of the immune response rather than directly repairing damaged nerves or restoring lost myelin.

What Types of Multiple Sclerosis Does Rebif Treat?

Rebif is FDA-approved for relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. Clinically isolated syndrome involves a first episode of neurological symptoms consistent with inflammatory demyelination. Relapsing-remitting MS involves episodes of new or worsening neurological symptoms followed by periods of partial or complete recovery. Active secondary progressive MS involves disease progression with ongoing inflammatory activity. Rebif is not specifically approved for primary progressive MS or for treating an acute relapse. A neurologist evaluates neurological findings, MRI results, relapse history, and other factors when choosing treatment.

How Is Rebif Administered?

Rebif is injected beneath the skin three times per week, with doses separated by at least 48 hours. The recommended maintenance dose is either 22 mcg or 44 mcg per injection. Treatment generally begins at approximately 20% of the target dose and increases over a four-week titration period to improve tolerability. Injections are preferably given on the same three days each week, around the same time of day, often in the late afternoon or evening. Patients should rotate injection sites, follow proper injection techniques, and dispose of used needles safely. Blood counts and liver function tests are recommended during treatment.

What Are the Side Effects and Warnings of Rebif?

Common adverse effects include flu-like symptoms, headache, fever, muscle aches, fatigue, and injection-site redness or discomfort. Serious risks include depression and suicidal thoughts, severe liver injury, reduced blood cell counts, and severe injection-site reactions, including tissue necrosis. Rebif can also cause allergic reactions, thrombotic microangiopathy, pulmonary arterial hypertension, and seizures. Clinicians monitor liver enzymes, blood counts, and other laboratory findings according to individual risk. Patients should report worsening depression, yellowing of the skin, unusual bruising, persistent shortness of breath, or severe changes at an injection site. Flu-like reactions may improve with gradual dose increases and clinician-recommended symptom management.

Common Questions About Rebif

Is Rebif the same as interferon beta-1a?

Yes. Rebif is a brand-name formulation of interferon beta-1a used to treat relapsing forms of multiple sclerosis in adults.

How often is Rebif injected?

Rebif is injected beneath the skin three times per week, with at least 48 hours between doses.

Can Rebif prevent multiple sclerosis relapses?

Rebif can reduce the frequency of MS relapses in eligible patients, although relapses can still occur during treatment.

Does Rebif require blood testing?

Yes. Monitoring commonly includes liver function tests and complete blood counts because Rebif can affect liver enzymes and blood cell levels.

References

Beta Interferon. LiverTox. https://www.ncbi.nlm.nih.gov/books/NBK548080/. Date Accessed November 3, 2026.

DailyMed - REBIF (interferon beta-1a) injection. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6fcb5d2-8fcd-44fa-a838-b84ee5f44f0f. Date Accessed November 3, 2026.

Interferon Beta-1A. PubChem. https://pubchem.ncbi.nlm.nih.gov/compound/Interferon-Beta-1A. Date Accessed November 3, 2026.

Interferon Beta-1a Subcutaneous Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a604005.html. Date Accessed November 3, 2026.

Rebif. European Medicines Agency. https://www.ema.europa.eu/en/medicines/human/EPAR/rebif. Date Accessed November 3, 2026.